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ABSTRACT
Exosomes are a subset of extracellular vesicles and their 
size is approximately 100 nm in diameter. They are 
surrounded by a lipid bilayer membrane and secreted 
from almost all of cells. Exosomes are generated within 
the endocytic system as ILV (intraluminal membrane 
vesicle) and secreted during the fusion of MVB (multi-
vesicular body) with the cell membrane. Recently it has 
been reported that exosomes modulate cell-cell commu-
nication contributing to the maintenance of tissue ho-
meostasis by molecules including exosomes. Moreover, 
exosomes released from cancer cells are involved in 
cancer progression. Thus, data regarding the role of the 
exosomes in malignant cancer will lead to development 
of novel diagnostic and therapeutic methods.
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Extracellular vesicles (EVs) are vesicles secreted by 
the cell and are classified into three groups, namely 
apoptotic bodies, microvesicles (MVs), and exosomes 
according to their size and mechanism of formation. 
Apoptotic bodies are vesicles of 1μm or more in 
diameter that are released from the apoptotic cells, and 
contain fragmented nuclei and intracellular organelle. 
While both MV and exosomes contain proteins and 
nucleic acids, their sizes differ, with MVs ranging from 
100 to 1,000 nm while exosomes are approximately 100 
nm in diameter. Based on the composition of RNA in 
each type of vesicle, apoptotic bodies primarily contain 
ribosomal RNA (rRNA), whereas MVs contain almost 
no RNA. Exosomes contain large amounts of low 
molecular weight RNA but not rRNA.1 While apoptotic 
bodies and MV are directly formed and released by 
the cell membrane, exosomes are secreted through the 
endocytosis of the multivesicular bodies (MVBs). Each 
vesicle also differs in the surface molecules expressed, 
such as phosphatidylserine (apoptotic bodies), integrin, 
secretin and CD40 (MVs), and tetraspanin (exosome). 
Although there have been studies regarding each type 
of vesicle, in recent years, research on exosomes has 
increased particularly, and there have been reports 
related to disease progression by exosome, in addi-
tion to understanding the biological significance of 
exosomes. In this review, we summarize an overview of 
the characteristics of the exosome and its involvement 
in cancer progression. Moreover, we discuss the issues 
in exosome research and future prospects for its clinical 
application.
OVERVIEW OF THE EXOSOME
History —From discovery to arriving on the front 
stage—
In 1983, Johnstone et al. discovered a 100 nm vesicle 
having a lipid bilayer structure secreted from the sheep 
reticulocytes2 and named the vesicle “exosome” in 1987. 
Exosomes were initially thought to play a garbage bag-
like role to eliminate unnecessary substances from the 
cells. However, it was shown in 1996 that exosomes 
secreted by the B lymphocytes induced activation of the 
T lymphocytes, thereby revealing that exosomes affect 
other cells.3 In 2007, Valadi and colleagues reported 
that exosomes encapsulated RNA and transferred them 
to other cells, as well as the fact that proteins encoded 
by the mRNA contained in the exosomes are expressed 
in cells receiving the exosome.4 Furthermore, in 2010, 
Kosaka, Pegtel, and Zhang et al. used different cell lines 
to show that microRNA (miRNA) encapsulated in the 
exosomes inhibited expression of the target genes in the 
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receiving cells.5–7 These reports revealed that exosomes 
are not merely garbage bags, but they function as tools 
of communication between cells, and this led to exo-
somes gathering more attention.
Biogenesis of exosomes
Exosomes originate from the endosome; thus they are 
differentiated from the previously mentioned apoptotic 
bodies and MV that are formed directly from the cell 
membrane.8 The initial endosome is formed by encapsu-
lating the cell membrane proteins through endocytosis 
and intracellular proteins and nucleic acids. This initial 
endosome matures into a late endosome through a 
maturation process which is accompanied by decreasing 
pH, and multiple ILV (intraluminal membrane vesicle) 
are formed inside the endosome, as if to sprout. Vesicle 
containing multiple ILVs are called MVBs, and the ILVs 
are released into the extracellular space as MVB fuses 
with the cell membrane again. These secreted ILVs are 
exosomes (Fig. 1).
The intracellular formation of ILV has been 
reported via two pathways; firstly, a pathway involv-
ing ESCRT (endosomal sorting complex required for 
transport) and, secondly a pathway independent of the 
ESCRT. In the former, proteins such as ESCRT-0, -I, -II, 
and -III form complexes and are involved in a series of 
ILV formation.9–11 In the latter, exosomes are secreted 
even when ESCRT is inhibited12 and instead involve 
ceramide and tetraspanin. Kosaka and colleagues have 
reported that exosome secretion is suppressed by inhibi-
tion of n-SMase2, an enzyme that promotes ceramide 
synthesis, and conversely, exosome secretion is pro-
moted by overexpression of n-SMase2.5, 13 In addition, 
van Niel et al. reported that CD63, a type of tetraspanin, 
is involved in protein transfer to ILV independent of 
ESCRT and ceramide.14
As a protein involved in extracellular release 
of ILV, that is, secretion of exosomes, the Rab fam-
ily, which is a small molecule GTP-binding protein 
involved in vesicular trafficking, is known. Among the 
RAB family, RAB 7,15 RAB 11,16 RAB 27 A,17 RAB 
27 B,17 and RAB 3518 regulate exosome secretion. 
Moreover, their involvement has also been confirmed in 
various cancer cells.19–21 The RAB family proteins are 
thought to be involved in the binding of MVBs to the 
cell membrane, but the associated RAB family protein 
differ from cell to cell. In addition to the RAB family 
protein, it has also been clarified that the p53 gene, 
which is a tumor suppressor gene, controls the secretion 
through its target gene TSAP6,22, 23 showing a glimpse 
of complexity involving various kinds of molecules. As 
described above, many molecules are involved during 
the formation of the exosomes, and multiple pathways 
have been reported, but the complete mechanism still 
Fig. 1. Biogenesis of Exosome.
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remains unknown.
Exosome structure and encapsulated substances
As mentioned above, exosomes are vesicles of approxi-
mately 100 nm in diameter consisting of a lipid bilayer 
and can be largely classified into membrane components 
and encapsulated molecules (Fig. 2). The membrane 
components consist of lipids and proteins, like a typi-
cal cell membrane. It has been reported that the lipid 
composition of the exosome membrane is dependent on 
the cell producing the exosome.24 Exosomal membranes 
contain more cholesterol, sphingolipids and phospha-
tidylserines, which are usually found on the inner side 
of cell membranes, are found on the outer side of exo-
some.25 As proteins existing in the exosome membrane, 
tetraspanins, such as CD9, CD63, CD81 etc., which are 
proteins with four transmembrane domains, MHC mol-
ecules that are proteins related to antigen presentation, 
and the cell adhesion molecule integrin were observed. 
Tetraspanin is used as a relatively specific exosome 
marker,26 and integrin is involved in exosome tropism.27
On the contrary, the encapsulated molecules in 
exosomes includes proteins and nucleic acids. The 
protein contains a large amount of heat shock and 
cytoskeletal proteins, as well as endosome-related 
proteins (SNARE, annexin, and flotillin), and Alix and 
TSG101 that are related to MVBs biosynthesis. Similar 
to the lipid composition, the protein composition is also 
known to change depending on the type of cell produc-
ing it and the surrounding microenvironment.28–31 
Nucleic acids encapsulated in the cells include RNA 
and DNA. On the former, the presence of miRNA,32 
IncRNA,33, 34 and circRNA35 etc., have been confirmed 
in addition to the mRNA.4, 36 Cells containing exosomes 
that have RNA molecules have been shown to translate 
mRNA into proteins,4 while the miRNA blocks transla-
tion.5–7 While there are many other non-coding RNAs 
in exosomes, they have been strongly suggested to be 
involved in transcription and translation processes in 
the exosome-received cells. On the latter, it has been 
reported that exosomes contain DNA, and Thakur et al. 
has demonstrated that using enzymes that specifically 
break down dsDNA and ssDNA respectively, most 
DNAs contained in the exosomes are dsDNAs.37 In 
recent years, Takahashi et al. showed that inhibition of 
exosome secretion by normal cells led to the accumula-
tion of nuclear DNA fragments, thereby causing cellular 
aging and induction of apoptosis.38 This suggests that 
the accumulation of harmful DNA fragments in the 
cytoplasm is released into the external environment 
using exosomes and the exosomes contribute to the 
maintenance of cellular homeostasis. While there are 
reports suggesting that DNA is encapsulated in the 
exosomes, Kawamura et al. showed that DNA is present 
on the surface of exosomes,39 and the significance of its 
localization needs to be elucidated.
Fig. 2. Main features of Exosome.
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The exosome database ExoCarta (www.exocarta.
org) contains a list of molecules present in the exosome. 
As of March 2019, 9,769 types of proteins, 3,408 types 
of mRNAs, 2,838 types of miRNAs, and 1,116 types 
of lipids have been registered. Moreover, the exosome 
constituents can be searched according to conditions 
like the animal species or cell type etc.
EXOSOME AND PROGRESSION OF CANCER
Proliferative cancer cells show (i) enlargement of cancer 
tissue with angiogenesis, (ii) acquisition of migratory 
and invasive capacity, and (iii) acquisition of capacity to 
avoid attack from immune cells and ultimately (iv) the 
formation of metastatic lesions. Based on the studies so 
far, it has become apparent that exosomes are involved 
in each of these processes (Fig. 3). Here, we describe 
the role of exosomes in each process.
Role of exosomes in the enlargement of cancer tis-
sue with angiogenesis
During tumor growth, it has been reported that angio-
genesis is induced when the tumor size exceeds 2 to 3 
mm in diameter.40 Angiogenesis plays an important role 
in supplying oxygen and nutrition to the cancer cells, 
and it is an essential phenomenon for enlargement of 
solid tumors, i.e. a primary lesion or a metastatic lesion.
In 2008, Skog et al. reported that exosomes 
secreted by the glioblastoma promotes angiogenesis, 
as it is taken in by vascular endothelial cells,41 while 
in 2009, Hong et al. reported that cell cycle-related 
mRNA contained in the exosome from the colon cancer 
cells promotes the proliferation of vascular endothelial 
cells.42 In 2011, Grande et al. reported that the exosomes 
secreted by the renal cancer cell line, CD105-positive 
exosomes affected vascular endothelial cells and pro-
moted growth, while CD105-negative exosomes had no 
such effect.43 Furthermore, Svensson et al. reported that 
exosome secreted by the glioblastoma under hypoxic 
environment had tissue factor and induced angiogenesis 
through the activation of PAR-2 in the vascular endo-
thelial cells.44 These reports suggest that the surface 
molecules on the exosomes secreted by the cancer cells 
differ according to their function and change according 
to the environment. Furthermore, Kosaka et al. demon-
strated that miR-210 contained in the exosomes secreted 
by breast cancer cells promotes angiogenesis and that 
suppression of exosome secretion from breast cancer 
cells by n-SMase2 knockdown can suppress metastasis 
through the inhibition of angiogenesis.13 In 2019, Li 
et al. reported that exosomes from the liver cancer 
cells are taken up by vascular endothelial cells and the 
LOXL4 in the exosomes acts to promote proliferation 
of the vascular endothelial cells.45 In the same year, Sun 
et al. reported that colon cancer-cell derived exosomes 
containing IRF-2 are taken up by the macrophages and 
induce VEGFC production, which then promotes lymph 
Fig. 3. Cancer progression regulated by “Exosome.”
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node metastasis through lymphatic endothelial cell 
proliferation and lymphatic vessel remodeling.46
Role of exosomes in cancer cell migration or inva-
sion
As cancer cells proliferate, metastasis occurs by de-
stroying the surrounding existing tissues. The migration 
and invasion of cancer cells is important in this process, 
and it is considered the first step to metastasis. The ex-
pression and activation of factors that degrade proteins 
are important in the invasion process.
In 2010, McCready et al. reported that HSP90α ex-
ists on the surface of the exosomes derived from cancer 
cells with high invasive capacity, acts in an autocrine 
manner, and activates plasminogen to enhance the inva-
sive capacity of cancer cells.47 While plasmin formed by 
activation of plasminogen is known to degrade the ex-
tracellular matrix, it has also been reported to contribute 
to cell migration and invasion through the degradation 
of E-cadherin, which plays a role in epithelial cell adhe-
sion,48 and therefore, it was believed that exosomes con-
taining HSP90α are involved in the invasion of cancer 
cells through the mechanism mentioned above. In 2016, 
Sakha et al. reported that exosomes secreted by highly 
metastatic oral squamous cell carcinoma contained a 
large amount of miR-1246, and introduction of these 
exosomes to lowly metastatic cells negatively controlled 
DENND2D, the target molecule of miR-1246 and 
thereby promoted the migratory and invasive capacity 
of the cell.49 In 2018, Guo et al. showed that migration 
and invasion were suppressed in Rab27A-KO melanoma 
cells, but there was no difference in the size and expres-
sion level of the exosomes secreted, compared to cells 
that showed a high expression of Rab27A.50 Comparison 
of the contents of exosomes derived from the two cell 
lines showed that Rab27A-KO cells had a decreased 
amount of gene product that promotes cell migration 
and invasion, which suggested the possibility of Rab27A 
being involved in the production of exosomes that have 
the capacity to promote invasion.
It has been reported that the interaction between 
fibroblasts present in the cancer tissue and exosomes 
is important for cancer cell migration and invasion. 
In 2009, Castellana et al. showed that the chemokine 
receptor CXCR1 is present on the surface of cells de-
rived from prostate cancer cells and that this increases 
the expression of the matrix metalloprotease (MMP) 
in fibroblasts through phosphorylation (=activation) 
of ERK.51 Although MMP is a representative of the 
enzymes that degrade the extracellular matrix and 
plays an important role in cancer cell invasion, thus, an 
environment convenient for cancer cells is produced by 
secretion of these enzymes not by the cancer cell itself 
but through by the surrounding fibroblasts. In 2012, 
Luga et al. reported that through interaction with exo-
somes secreted by fibroblasts around breast cancer cells, 
breast cancer cells secrete exosomes containing Wnt, 
which acts on other surrounding breast cancer cells and 
promotes migration and invasion.52 Fibroblasts present 
in cancer tissue are called cancer-associated fibroblasts 
(CAFs). These fibroblasts are known to contribute to 
forming a favorable environment for cancer cells, and 
exosomes are used for interaction between cancer cells 
and CAFs.
Exosomes and their role in avoiding attack from 
the immune cells
For cancer cells to continue surviving and proliferating, 
it is necessary for them to avoid interaction with the 
immune cells. Starting with the proliferation in primary 
lesions, it is necessary for cancer cells to avoid being 
attacked by immune cells even while moving around in 
vessels.
In 2005, Huber et al. reported that the Fas ligand 
expressed on the surface of the exosomes derived from 
colon cancer cells thereby induced apoptosis of the 
T cells.53 Moreover, in 2006, Liu et al. reported that 
exosomes derived from breast cancer cells contribute to 
growth of tumor by blocking IL-2-mediated prolifera-
tion and activation of NK cell.54 Similarly, Clayton et 
al. reported that exosomes derived from the cancer cells 
suppress the expression of NKG2D that is necessary for 
activation of NK cells.55 In 2007, Yu et al. revealed that 
exosomes derived from breast cancer cells act on the 
CD11-positive cells in the bone marrow, promoting IL-6 
secretion and ultimately suppressing the differentiation 
of the dendritic cells.56 In 2014, Zhou et al. reported that 
miR-203 encapsulated in the exosomes derived from the 
pancreatic cancer cells inhibits the expression of TLR4 
(toll-like receptor 4), which is a foreign body recogni-
tion receptor in dendritic cells.57 Moreover, de Vrij et 
al. reported in 2015 that exosomes derived from glioma 
induce differentiation of monocytes into immunosup-
pressive macrophages.58
Thus, exosomes derived from the cancer cells 
induce death of the immune cells or inhibit their activa-
tion or differentiation in the body to play an important 
role in helping cancer cells avoid attacks by such cells.
Exosomes and their role in formation of metastatic 
niche
The metastasis of cancer is the hallmark of malignant 
cancer, and it is an important prognostic factor clini-
cally. Exosomes are actively involved in the formation 
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of metastatic lesions, and under certain conditions 
exosomes promote metastasis when they are secreted 
by cancer cells with the purpose of metastasis, or when 
exosomes, secreted from the primary lesion, reach a 
distant organ through the blood.
As mentioned previously, cells that migrate from 
the primary lesion and reach a distant organ through 
the blood vessels, while avoiding attacks from immune 
cells, migrate from the blood vessel to the tissue. In 
2014, Zhou et al. reported that exosomes derived from 
the metastatic breast cancer tissue contain miR-105, 
and by acting on the vascular endothelial cells, these 
exosomes downregulate the expression of the adhesion 
molecule ZO-1, ultimately promoting migration of 
cancer cells out of the blood vessels.59 In addition, a 
positive correlation was shown between the miR-105 
content in the blood exosomes and distant metastasis in 
human breast cancer patients, which strongly suggested 
the importance of miR-105. In 2015, Tominaga et al. 
identified the exosome related to disruption of the blood-
brain-barrier (BBB) that controls the movement of 
substances in and out of the brain.60 miR-181c contained 
in the exosomes derived from the breast cancer cells 
that metastasize to the brain inhibits PDPK1 and inhib-
its polymerization of actin in the cytoskeleton, which 
results in morphological changes. This changes the 
structure of the vascular endothelial cells that compose 
the BBB, producing gaps between cells and promotes 
the migration of the breast cancer cells into the brain 
parenchyma. This report was epochal. Furthermore, in 
2017, an exosome related to the peritoneal dissemination 
of ovarian cancer was identified. Yokoi et al. reported 
that as exosomes derived from the metastatic ovarian 
cancer cells were taken up by the mesothelial cells 
composing the peritoneum, they induced apoptosis and 
led to formation of a hole in the peritoneum, leading to 
peritoneal dissemination of the cancer.61 This exosome 
contained MMP-1 mRNA, and it has been shown that 
this mRNA is translated to its protein in the mesothelial 
cells.
While the mechanism by which exosome secreted 
by cancer cells acts on the target tissue has been eluci-
dated, it has also been shown that exosomes secreted 
by the primary lesion lead to the formation of the 
metastatic lesion in distant tissues (i.e., pre-metastatic 
niche formation) before the cancer cells themselves 
migrate to the particular tissue. In 2012, Peinado et al. 
revealed that when exosomes derived from melanoma 
cells, with highly metastatic potential to the lungs, were 
administered to mice, they promoted vascular perme-
ability through introduction of bone marrow cells to 
the lungs and thereby contributed to the formation of a 
pre-metastatic niche.20 In fact, it has been reported that 
administration of the exosome prior to transplantation 
of melanoma cells to mice promoted metastasis in 
those mice, compared to mice that were devoid of the 
exosomes. In 2015, Costa-Silva et al. reported that exo-
somes derived from the pancreatic cancer cells formed 
the pre-metastatic niche for liver metastasis.62 Pancreatic 
cancer cell-derived exosomes contain the macrophage 
migration inhibitory factor, and the hepatic Kuppfer 
cells that took in these exosomes induced fibronectin 
production by hepatic stellate cells through production 
of TGF-beta and ultimately formed a pre-metastatic 
niche through introduction of bone marrow cells to the 
liver. As normal pancreatic tissue-derived exosomes 
do not show such phenomena, the pre-metastatic niche 
formation was thought to be due to pancreatic cancer 
cell-derived exosomes. As such, it was understood 
that exosomes secreted by cancer cells were involved 
in the formation of pre-metastatic niche, and there are 
questions regarding the function of the exosomes in 
specific organs. Hoshino et al. have reported that this is 
dependent on the pattern of integrins on the surface of 
the exosomes secreted by the cancer cells.27 Hoshino et 
al. showed that exosomes, showing tropism to the lungs, 
have integrin α6β4 and α6β1, while exosomes showing 
tropism to the liver have αvβ5. In addition to the forma-
tion of a pre-metastatic niche in the lungs and liver by 
the respective exosomes, downregulation of the specific 
integrin expressions in the exosomes weakened their 
respective tropism and subsequently suppressed the me-
tastasis of cancer cells secreting these exosomes. Thus, 
these reports partially, demonstrated the “Seed and soil 
hypothesis” proposed by Paget in 1889 at the molecular 
level.
PROSPECT OF THE CLINICAL APPLICATION 
OF EXOSOME RESEARCH AND FUTURE 
CHALLENGES
As the role of exosomes in cancer progression become 
clearer, there have been increasing efforts towards their 
clinical application, and in recent years, cancer diagno-
sis by liquid biopsy has gained attention. Liquid biopsy 
is a method of diagnosis that analyzes the disease infor-
mation contained in body fluids like blood, and cancer 
cell-derived exosomes are certainly one such type 
of information. As a novel diagnostic technology for 
colon cancer, Yoshioka et al. developed the “ExoScreen 
method.”63 This is a quick and easy method for detect-
ing colon cancer cell-derived exosomes contained in 
the blood. This method works by trapping the exosome, 
using two types of monoclonal antibodies, one against 
the general exosome marker CD9 and the other against 
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the colon cancer cell-derived exosome-specific marker 
CD147. When the two antibodies are in close proximity 
i.e. within 200 nm, a fluorescence signal is generated. 
As such, if we are able to identify a molecule that is 
specifically present in the exosomes derived from can-
cer cells, either for all cancers in general or individual 
cancer types, this can provide an epochal diagnostic 
marker for cancer(s). Furthermore, if exosomes contain 
information related to pathology or drug resistance, it 
would prove to be a useful marker for understanding 
patient condition or for choosing a treatment. In addition 
to diagnosis using exosomes, development of treatments 
targeting exosomes is underway at the research level. 
Nishida-Aoki et al. produced a mouse model with breast 
cancer by orthotopic transplantation of human breast 
cancer cell line and administered antibodies against 
human CD9 or CD63 to these mice. Whereas mice 
without antibody administration showed lymph node 
and lung metastasis of the cancer, use of antibodies 
against cancer cell-derived exosomes have been shown 
to suppress cancer metastasis in the models.64 Although 
the antibodies used in the study showed a reaction spe-
cific to breast cancer cell-derived exosomes because the 
cancer cell and the host species are different from one 
another, the report strongly suggested that identification 
of cancer cell-specific exosomal surface marker(s) will 
be able to lead to a novel treatment against cancers. 
Furthermore, by using molecules that specify the 
tropism of an exosome as described in 2.4, exosomes 
will enable the use as a drug delivery system (DDS). 
Therefore, exosomes can be expected to develop as a 
diagnostic marker, a therapeutic target, and for drug 
discovery and has the potential to change the future of 
medicine.
CONCLUSION
This review provides an overview of exosomes and its 
role in cancer progression. Although exosomes were 
discovered 40 years ago, in the 1980s, there has been 
a dramatic progression in research intended for under-
standing their biological significance and application 
to medicine. However, there are many details that still 
remain unknown, and new questions arise based on 
recent research. For instance, while the content of exo-
somes varies among cells and changes even for the same 
cell depending on the environment, the mechanism for 
this variety is yet to be understood. Elucidating the role 
of the molecules on the exosomal surface and those 
encapsulated within would help reveal the pathological 
condition caused by the exosome and develop methods 
to counter them. With the exosome as a key word, 
basic researchers and clinical researchers need to take 
a challenge to overcome “cancer,” and we believe there 
will be a significant breakthrough.
The authors declare no conflict of interest.
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